Cost and cost drivers associated with setting-up a prime vendor system to complement the national medicines supply chain in Tanzania.


Journal

BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275

Informations de publication

Date de publication:
09 2020
Historique:
received: 20 04 2020
revised: 24 06 2020
accepted: 15 07 2020
entrez: 15 9 2020
pubmed: 16 9 2020
medline: 25 6 2021
Statut: ppublish

Résumé

Economic analysis of supply chain management interventions to improve the availability of healthcare commodities at healthcare facilities is important in generating evidence for decision-makers. The current study assesses the cost and cost drivers for setting-up a public-private partnership programme in Tanzania in which all public healthcare facility orders for complementary medicines are pooled at the district level, and then purchased from one contracted supplier, the prime vendor (referred to as 'Jazia Prime Vendor System' (Jazia PVS)). Financial and economic costs of Jazia PVS were collected retrospectively and using the ingredients approach. The financial costs were spread over the implementation period of January 2014-July 2019. In addition, we estimated the financial rollout costs of Jazia PVS to the other 23 regions in the country over 2 years (2018-2019). A multivariate sensitivity analysis was conducted on the estimates. Jazia PVS start-up and recurrent financial costs amounted to US$2 170 989.74 and US$709 302.32, respectively. The main cost drivers were costs for short-term experts, training of staff and healthcare workers and the Jazia PVS technical and board management activities. The start-up financial cost per facility was US$2819.47 and cost per capita was US$0.37. In conclusion, the study provides useful information on the cost and cost drivers for setting-up a complementary pharmaceutical supply system to complement an existing system in low-income settings. Despite the substantial costs incurred in the initial investment and operations of the Jazia PVS, the new framework is effective in achieving the desired purpose of improving availability of healthcare commodities.

Identifiants

pubmed: 32928801
pii: bmjgh-2020-002681
doi: 10.1136/bmjgh-2020-002681
pmc: PMC7490950
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Health Policy Plan. 2005 Mar;20(2):124-36
pubmed: 15746221
Afr J Lab Med. 2015;4(1):
pubmed: 26900573
Health Policy Plan. 2000 Jun;15(2):145-56
pubmed: 10837037
Glob Health Sci Pract. 2017 Sep 28;5(3):399-411
pubmed: 28877933
Health Policy Plan. 2000 Jun;15(2):230-4
pubmed: 10837047
Cost Eff Resour Alloc. 2003 Feb 26;1(1):1
pubmed: 12773220
Glob Health Action. 2019;12(1):1670014
pubmed: 31573421
BMJ Glob Health. 2018 Jun 4;3(3):e000762
pubmed: 29915670
Value Health Reg Issues. 2016 May;9:78-83
pubmed: 27881265
BMJ Glob Health. 2017 Apr 13;2(2):e000243
pubmed: 28589028
Value Health. 2019 Sep;22(9):1026-1032
pubmed: 31511179
Soc Sci Med. 1992 Oct;35(8):1015-25
pubmed: 1411696
BMJ. 1999 Sep 4;319(7210):635-8
pubmed: 10473486
BMC Health Serv Res. 2011 May 27;11:128
pubmed: 21619567
Trop Med Int Health. 2011 May;16(5):647-58
pubmed: 21342375
Public Health. 2015 Jul;129(7):899-906
pubmed: 26027451
Eur J Clin Pharmacol. 2004 May;60(3):149-53
pubmed: 15057496
Value Health. 2000 Jul-Aug;3(4):277-86
pubmed: 16464192
Health Econ. 2015 Feb;24(2):238-52
pubmed: 24293058
Health Econ. 2016 Feb;25 Suppl 1:53-66
pubmed: 26763594
J Pharm Policy Pract. 2019 Feb 25;12:4
pubmed: 30891247
Syst Rev. 2014 May 21;3:47
pubmed: 24887208
JMIR Res Protoc. 2018 Sep 13;7(9):e10163
pubmed: 30213780
Health Policy Plan. 2006 Jul;21(4):275-88
pubmed: 16682433
Med Care. 2009 Jul;47(7 Suppl 1):S76-81
pubmed: 19536026
BMC Health Serv Res. 2018 Nov 23;18(1):886
pubmed: 30470214
Health Policy Plan. 2019 Apr 1;34(3):188-196
pubmed: 31004143
Glob Health Action. 2014 Mar 28;7:23573
pubmed: 24685170
Health Syst Reform. 2019;5(2):158-177
pubmed: 31194645
Glob Health Action. 2014 Feb 13;7:23568
pubmed: 24560261

Auteurs

August Kuwawenaruwa (A)

Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania ajoachim@ihi.or.tz.
University of Basel, Basel, Switzerland.
Swiss Tropical and Public Health Institute (Swiss TPH), Basel, Switzerland.

Kaspar Wyss (K)

University of Basel, Basel, Switzerland.
Swiss Tropical and Public Health Institute (Swiss TPH), Basel, Switzerland.

Karin Wiedenmayer (K)

University of Basel, Basel, Switzerland.
Swiss Tropical and Public Health Institute (Swiss TPH), Basel, Switzerland.
Health Promotion and System Strengthening (HPSS) project, Dodoma, United Republic of Tanzania.

Fabrizio Tediosi (F)

University of Basel, Basel, Switzerland.
Swiss Tropical and Public Health Institute (Swiss TPH), Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH